Kaoru Irisa

Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer

Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo et al. · Journal of Thoracic Oncology · 2010 · 130 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis

Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo et al. · Journal of Thoracic Oncology · 2010 · 55 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I)

Katsuhiro Masago, Shiro Fujita, Kaoru Irisa et al. · Japanese Journal of Clinical Oncology · 2010 · 51 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of vascular endothelial growth factor polymorphisms on survival in advanced‐stage non‐small‐cell lung cancer

Katsuhiro Masago, Shiro Fujita, Yung Haku Kim et al. · Cancer Science · 2009 · 36 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib

Katsuhiro Masago, Shiro Fujita, Yosuke Togashi et al. · Oncology · 2010 · 22 citations

Medicine, Molecular Medicine, Oncology +17